Last reviewed · How we verify
Guselkumab Intravenous
Guselkumab Intravenous is a Small molecule drug developed by Janssen Research & Development, LLC. It is currently in Phase 3 development. Also known as: CNTO1959, TREMFYA.
At a glance
| Generic name | Guselkumab Intravenous |
|---|---|
| Also known as | CNTO1959, TREMFYA |
| Sponsor | Janssen Research & Development, LLC |
| Modality | Small molecule |
| Phase | Phase 3 |
Approved indications
Common side effects
- Pyrexia
- Headache
- Nasopharyngitis
- Colitis Ulcerative
- Dermatitis Contact
- Anaemia
- Upper Respiratory Tract Infection
- Paronychia
- Tinea Pedis
- Malaise
- Folliculitis
- Arthropod Sting
Key clinical trials
- A Study of the Efficacy and Safety of Guselkumab in Participants With Moderately to Severely Active Crohn's Disease (PHASE2, PHASE3)
- A Study of Guselkumab in Pediatric Participants With Moderately to Severely Active Ulcerative Colitis (PHASE3)
- A Study of Guselkumab in Participants With Fistulizing, Perianal Crohn's Disease (PHASE3)
- Guselkumab Vs Ustekinumab in Stricturing Crohn's Disease
- A Study of Guselkumab in Participants With Moderately to Severely Active Crohn's Disease (PHASE3)
- Immunosuppressant Management in Rheumatology Patients Undergoing Elective Total Shoulder Arthroplasty (PHASE2)
- A Study of Guselkumab in Participants With Systemic Sclerosis (PHASE2)
- GUselkumAb inteRvention and DIet evaluAtioN for Pouchitis (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Guselkumab Intravenous CI brief — competitive landscape report
- Guselkumab Intravenous updates RSS · CI watch RSS
- Janssen Research & Development, LLC portfolio CI
Frequently asked questions about Guselkumab Intravenous
What is Guselkumab Intravenous?
Guselkumab Intravenous is a Small molecule drug developed by Janssen Research & Development, LLC.
Who makes Guselkumab Intravenous?
Guselkumab Intravenous is developed by Janssen Research & Development, LLC (see full Janssen Research & Development, LLC pipeline at /company/johnson-johnson).
Is Guselkumab Intravenous also known as anything else?
Guselkumab Intravenous is also known as CNTO1959, TREMFYA.
What development phase is Guselkumab Intravenous in?
Guselkumab Intravenous is in Phase 3.
What are the side effects of Guselkumab Intravenous?
Common side effects of Guselkumab Intravenous include Pyrexia, Headache, Nasopharyngitis, Colitis Ulcerative, Dermatitis Contact, Anaemia.
Related
- Manufacturer: Janssen Research & Development, LLC — full pipeline
- Also known as: CNTO1959, TREMFYA
- Compare: Guselkumab Intravenous vs similar drugs
- Pricing: Guselkumab Intravenous cost, discount & access